|
1）Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014; 312: 2510-20
|
|
|
|
2）Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60
|
|
|
|
|
|
3）Barnett H, Burrill P, Iheanacho I. Donʼt use aspirin for primary prevention of cardiovascular disease. BMJ. 2010; 340: c1805
|
|
|
|
|
|
4）Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012; 172: 209-16
|
|
|
|
|
|
5）(FDA) FaDA. Use of Aspirin for Primary Prevention of Heart Attack and Stroke. http: //wwwfdagov/drugs/resourcesforyou/consumers/ucm390574htm. 2014
|
|
|
|
|
|
6）Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300: 2134-41
|
|
|
|
|
|
7）Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371: 2155-66
|
|
|
|
|
|
8）Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310: 2510-22
|
|
|
|
|
|
9）Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015; 350: h1618
|
|
|
|
|
|
10）Spencer FA, Prasad M, Vandvik PO, et al. Longer- versus shorter-duration dual-antiplatelet therapy after drug-eluting stent placement: A systematic review and meta-analysis. Ann Intern Med. 2015; 163: 118-26
|
|
|
|
|
|
11）Cassese S, Byrne RA, Tada T, et al. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J. 2012; 33: 3078-87
|
|
|
|
|
|
12）Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800
|
|
|
|
|
|
13）Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35: 3155-79
|
|
|
|
|
|
14）Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-15
|
|
|
|
|
|
15）Capodanno D, Lip GY, Windecker S, et al. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention. 2015; 10: 1015-21
|
|
|
|
|
|
16）Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010; 9: 959-68
|
|
|
|
|
|
17）Uchiyama S, Tanahashi N, Minematsu K, et al. Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke. Cerebrovasc Dis. 2012; 34: 229-39
|
|
|
|
|
|
18）Investigators SPS, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012; 367: 817-25
|
|
|
|
|
|
19）Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010; 376: 1320-8
|
|
|
|
|
|
20）Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361: 2318-29
|
|
|
|
|
|
21）Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009; 361: 2330-41
|
|
|
|
|